SG11201906663VA - Bone-targeting antibodies - Google Patents
Bone-targeting antibodiesInfo
- Publication number
- SG11201906663VA SG11201906663VA SG11201906663VA SG11201906663VA SG11201906663VA SG 11201906663V A SG11201906663V A SG 11201906663VA SG 11201906663V A SG11201906663V A SG 11201906663VA SG 11201906663V A SG11201906663V A SG 11201906663VA SG 11201906663V A SG11201906663V A SG 11201906663VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- antibodies
- bridgewater
- sanofi
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIP0 I PCT omit IIl °nolo io (10) International Publication Number WO 2018/136698 A2 (51) International Patent Classification: CO7K 16/22 (2006.01) (21) International Application Number: PCT/US2018/014350 (22) International Filing Date: 19 January 2018 (19.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/448,763 20 January 2017 (20.01.2017) US (71) Applicant: GENZYME CORPORATION [US/US]; 50 Binney Street, Cambridge, MA 02142 (US). (72) Inventors: QIU, Huawei; c/o Sanofi, 55 Corporate Dri- ve, Mail Code: 55A-505A, Bridgewater, NJ 08807 (US). PARK, Sunghae; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, NJ 08807 (US). STE- FANO, James; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, NJ 08807 (US). (74) Agent: LI, Z., Ying et al.; Steptoe & Johnson LLP, 1330 Connecticut Avenue, NW, Washington, DC 20036 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: BONE-TARGETING ANTIBODIES FIG. 1 a-TG 93 antibody (57) : Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly- = aspartate (poly-D) peptides {e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making C and using of these antibodies and fragments also are disclosed. [Continued on next page] WO 2018/136698 A2 MIMMIMOHNIIMEIE30111110111HIMIEHOE# Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762448763P | 2017-01-20 | 2017-01-20 | |
PCT/US2018/014350 WO2018136698A2 (en) | 2017-01-20 | 2018-01-19 | Bone-targeting antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906663VA true SG11201906663VA (en) | 2019-08-27 |
Family
ID=61581744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906663VA SG11201906663VA (en) | 2017-01-20 | 2018-01-19 | Bone-targeting antibodies |
Country Status (17)
Country | Link |
---|---|
US (2) | US10844115B2 (en) |
EP (1) | EP3571226A2 (en) |
JP (2) | JP7227138B2 (en) |
KR (2) | KR102613463B1 (en) |
CN (1) | CN111032690B (en) |
AR (1) | AR110755A1 (en) |
AU (1) | AU2018210270A1 (en) |
BR (1) | BR112019013986A2 (en) |
CA (1) | CA3050884A1 (en) |
IL (1) | IL268114A (en) |
MX (2) | MX2019008549A (en) |
MY (1) | MY194819A (en) |
SG (1) | SG11201906663VA (en) |
TW (2) | TWI788321B (en) |
UY (1) | UY37576A (en) |
WO (1) | WO2018136698A2 (en) |
ZA (1) | ZA201907673B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3496755A4 (en) * | 2016-08-11 | 2020-03-11 | Precithera, Inc. | Tgf- antagonist conjugates |
WO2022235796A1 (en) | 2021-05-07 | 2022-11-10 | Baylor College Of Medicine | Treatment of moderate-to-severe osteogenesis imperfecta |
CA3226401A1 (en) * | 2021-07-20 | 2023-01-26 | William Marsh Rice University | Engineered compositions for bone-targeted therapy |
CA3237245A1 (en) | 2021-11-01 | 2023-05-04 | Genzyme Corporation | Treatment of osteogenesis imperfecta |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5824655A (en) | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
CN1300173C (en) | 1996-02-09 | 2007-02-14 | 艾博特生物技术有限公司 | Human antibodies that bind huma TNF 'alpha' |
CA2280957A1 (en) | 1997-02-14 | 1998-08-20 | Leslie Orgel | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents |
EP1074563A1 (en) * | 1999-08-02 | 2001-02-07 | F. Hoffmann-La Roche Ag | Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof |
US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
NZ571243A (en) | 2002-12-31 | 2010-04-30 | Altus Pharmaceuticals Inc | Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine |
WO2004098637A1 (en) | 2003-04-30 | 2004-11-18 | Genzyme Corporation | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
EP1646655A2 (en) | 2003-07-09 | 2006-04-19 | Eli Lilly And Company | Tgf-beta1 ligands |
NZ550217A (en) | 2004-03-31 | 2009-11-27 | Genentech Inc | Humanized anti-TGF-beta antibodies |
SI3404102T1 (en) | 2004-04-21 | 2021-11-30 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
CA2597098C (en) | 2005-02-08 | 2016-08-02 | Steven R. Ledbetter | Antibodies to tgfbeta |
TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
US8574577B2 (en) * | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
BRPI0821906B1 (en) * | 2008-01-03 | 2022-06-07 | The Scripps Research Institute | Isolated full-length antibody, its use, polynucleotide, vector, and host cell |
PE20110435A1 (en) | 2008-08-25 | 2011-07-20 | Amplimmune Inc | ANTAGONIST COMPOSITIONS OF PD-1 |
RU2562114C2 (en) * | 2008-12-22 | 2015-09-10 | Ново Нордиск А/С | Antibodies against inhibitor of tissue factor metabolic pathway |
US20120294868A1 (en) | 2009-04-24 | 2012-11-22 | Edwards James R | Anti-tgf-beta induction of bone cell function and bone growth |
US8993524B2 (en) | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
EP2714735B1 (en) | 2011-06-03 | 2021-07-21 | XOMA Technology Ltd. | Antibodies specific for tgf-beta |
US20130209449A9 (en) * | 2011-06-13 | 2013-08-15 | Abgenomics Cooperatief U.A. | Anti-psgl-1 antibodies and uses thereof |
SG11201401605QA (en) * | 2011-10-19 | 2014-09-26 | Alexion Pharma Holding | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
US10052366B2 (en) * | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
AU2013269652B2 (en) * | 2012-05-31 | 2017-07-06 | Innate Pharma | TLR3 binding agents |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
WO2014062978A1 (en) | 2012-10-17 | 2014-04-24 | Cedars-Sinai Medical Center | Molecular signatures of ovarian cancer |
UY35493A (en) * | 2013-03-20 | 2014-11-28 | Genzyme Corp | METHODS FOR THE TREATMENT OF IMPERFECT OSTEOGENESIS |
CA2911514A1 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
PL3702373T3 (en) | 2013-09-13 | 2022-12-05 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
WO2015140150A1 (en) | 2014-03-17 | 2015-09-24 | Piotr Jachimczak | Combination for use in a method of treating cancer |
US20180265874A1 (en) | 2014-10-10 | 2018-09-20 | Global Biopharma, Inc. | Methods for treating and/or preventing a tumor growth, invasion and/or metastasis |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
CN113577264A (en) | 2015-04-17 | 2021-11-02 | 百时美施贵宝公司 | Compositions comprising a combination of an anti-PD-1 antibody and an additional antibody |
WO2017011773A2 (en) | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Codon-optimized nucleic acids encoding antibodies |
EP3344660A4 (en) | 2015-08-31 | 2019-07-03 | National Research Council of Canada | Tgf- -receptor ectodomain fusion molecules and uses thereof |
EP3496755A4 (en) * | 2016-08-11 | 2020-03-11 | Precithera, Inc. | Tgf- antagonist conjugates |
-
2018
- 2018-01-18 TW TW107101790A patent/TWI788321B/en active
- 2018-01-18 AR ARP180100119A patent/AR110755A1/en unknown
- 2018-01-18 TW TW111146907A patent/TWI832600B/en active
- 2018-01-19 KR KR1020197024021A patent/KR102613463B1/en active IP Right Grant
- 2018-01-19 JP JP2019539277A patent/JP7227138B2/en active Active
- 2018-01-19 WO PCT/US2018/014350 patent/WO2018136698A2/en unknown
- 2018-01-19 KR KR1020237042558A patent/KR20230172039A/en not_active Application Discontinuation
- 2018-01-19 BR BR112019013986-9A patent/BR112019013986A2/en not_active IP Right Cessation
- 2018-01-19 MY MYPI2019006821A patent/MY194819A/en unknown
- 2018-01-19 MX MX2019008549A patent/MX2019008549A/en unknown
- 2018-01-19 CN CN201880007783.2A patent/CN111032690B/en active Active
- 2018-01-19 AU AU2018210270A patent/AU2018210270A1/en not_active Abandoned
- 2018-01-19 UY UY0001037576A patent/UY37576A/en not_active Application Discontinuation
- 2018-01-19 CA CA3050884A patent/CA3050884A1/en active Pending
- 2018-01-19 EP EP18709437.0A patent/EP3571226A2/en active Pending
- 2018-01-19 SG SG11201906663VA patent/SG11201906663VA/en unknown
- 2018-01-19 US US15/875,125 patent/US10844115B2/en active Active
-
2019
- 2019-07-16 IL IL268114A patent/IL268114A/en unknown
- 2019-07-17 MX MX2022008073A patent/MX2022008073A/en unknown
- 2019-11-20 ZA ZA2019/07673A patent/ZA201907673B/en unknown
-
2020
- 2020-10-23 US US17/079,285 patent/US20210163584A1/en active Pending
-
2023
- 2023-02-08 JP JP2023017271A patent/JP2023058590A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2019126026A3 (en) | 2021-11-09 |
AR110755A1 (en) | 2019-05-02 |
KR102613463B1 (en) | 2023-12-15 |
MX2022008073A (en) | 2022-07-27 |
CN111032690B (en) | 2024-03-26 |
US20180208650A1 (en) | 2018-07-26 |
US20210163584A1 (en) | 2021-06-03 |
TW202330597A (en) | 2023-08-01 |
TWI832600B (en) | 2024-02-11 |
JP7227138B2 (en) | 2023-02-21 |
EP3571226A2 (en) | 2019-11-27 |
KR20230172039A (en) | 2023-12-21 |
MX2019008549A (en) | 2019-09-11 |
RU2019126026A (en) | 2021-02-20 |
JP2020505919A (en) | 2020-02-27 |
UY37576A (en) | 2018-10-31 |
MY194819A (en) | 2022-12-17 |
WO2018136698A3 (en) | 2018-08-30 |
JP2023058590A (en) | 2023-04-25 |
ZA201907673B (en) | 2021-05-26 |
KR20190105236A (en) | 2019-09-16 |
IL268114A (en) | 2019-09-26 |
TW201839013A (en) | 2018-11-01 |
TWI788321B (en) | 2023-01-01 |
CN111032690A (en) | 2020-04-17 |
CA3050884A1 (en) | 2018-07-26 |
US10844115B2 (en) | 2020-11-24 |
BR112019013986A2 (en) | 2020-03-03 |
WO2018136698A2 (en) | 2018-07-26 |
AU2018210270A1 (en) | 2019-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201909652WA (en) | Neoantigen identification, manufacture, and use | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11202000073XA (en) | Anti-cd8 antibodies and uses thereof | |
SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201810327XA (en) | Single domain serum albumin binding protein | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201906663VA (en) | Bone-targeting antibodies | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
SG11201805420SA (en) | Antibodies and conjugates thereof | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201806639VA (en) | New streptococcal proteases | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
SG11201909561RA (en) | Octree-based convolutional neural network | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201810872UA (en) | Composition and method for reducing neutropenia | |
SG11201901220XA (en) | Methods of processing a fluid including a recombinant therapeutic protein and use thereof | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
SG11201804721SA (en) | Modulators of complement activity |